Drug Approval | March 12, 2022
China approves BeiGene’s tislelizumab
Tislelizumab is now approved for seven indications in China
Tislelizumab is now approved for seven indications in China
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
At the new centre, customers get a real-time experience of the process of genetic testing and actionable plans in preventive healthcare under the expertise of certified genetic counsellors
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
The facility will manufacture its Herceptin biosimilar, Tuznue
Subscribe To Our Newsletter & Stay Updated
